文献速递肾小球疾病肾移植

既往移植物复发FSGS患者的预防性治疗

Prophylactic treatment of FSGS recurrence in patients who relapsed on a previous kidney graft.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

这项法国多中心回顾性研究纳入66例既往移植肾FSGS复发患者,40例接受预防性治疗(静脉环孢素和/或利妥昔单抗和/或血浆置换),26例未接受。提示不应常规预防性治疗。

要点

  • 既往移植肾FSGS复发患者再次移植后复发率高达72.7%。

核心结论

  • 对于既往移植肾FSGS复发的患者,再次移植时不建议常规使用预防性治疗。
  • 无论是否使用预防性治疗,复发率均较高,但5年移植物存活率仍令人满意。

研究设计与样本

  • 回顾性多中心观察性研究,纳入法国25个移植中心。
  • 共识别66例患者:40例接受预防性治疗(PT+),26例未接受预防性治疗(PT-)。

主要发现

  • PT+组包括静脉环孢素和/或利妥昔单抗和/或血浆置换。
  • 两组进展至终末期肾病的時間相似。
  • PT+组诊断FSGS时和再次肾移植时更年轻,且既往移植物丧失更快。
  • 至少部分缓解率达87.5%。

临床怎么用

  • 对于既往移植肾FSGS复发的患者,再次移植前应与患者充分讨论预防性治疗的有限获益。
  • 不推荐常规使用静脉环孢素、利妥昔单抗或血浆置换进行预防。

局限性

  • 回顾性观察性研究,样本量较小(66例)。
  • 预防性治疗方案异质,包括不同药物组合。
  • 两组基线特征存在差异(PT+组更年轻、既往移植物丧失更快)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrence of focal segmental glomerulosclerosis (FSGS) is common after kidney transplantation and is classically associated with a significant decrease in graft survival. A major risk factor is a prior history of FSGS recurrence on a previous graft. This analysis reports the impact of a prophylactic treatment of FSGS recurrence in very high-risk patients who experienced a recurrence on a previous graft. METHODS: We performed a retrospective multicentre observational study in 25 French transplantation centres. The inclusion criteria were patients aged more than 18 years who had undergone kidney transplant between 31 December 2004 and 31 December 2020, and who had a history of FSGS recurrence on a previous graft. RESULTS: We identified 66 patients: 40 received prophylactic treatment (PT+), including intravenous cyclosporine and/or rituximab and/or plasmapheresis, and 26 did not receive any prophylactic treatment (PT-). The time to progression to end-stage kidney disease was similar between groups. The PT+ group was younger at FSGS diagnosis and at the time of kidney retransplantation and lost their previous graft faster. The overall recurrence rate was 72.7% (76.9% in the PT- group and 70.0% in the PT+ group, P = .54). At least partial remission was achieved in 87.5% of patients. The 5-year graft survival was 67.7% [95% confidence interval (CI) 53.4%-78.4%]: 65.1% (95% CI 48.7%-77.4%) in patients with FSGS recurrence vs 77.3% (95% CI 43.8%-92.3%) in patients without recurrence (P = .48). CONCLUSION: Our study suggests that prophylactic treatment should not be used routinely in patients receiving a second transplantation after recurrence of FSGS on a previous graft. The recurrence rate is high regardless of the use of prophylactic treatment. However, the 5-year graft survival remains satisfactory.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Uro-Coste C, Lambert C, Audard V, et al. Prophylactic treatment of FSGS recurrence in patients who relapsed on a previous kidney graft. Nephrol Dial Transplant. 2025. PMID: 38794882. doi:10.1093/ndt/gfae108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。